GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibitor Therapeutics Inc (OTCPK:INTI) » Definitions » Total Stockholders Equity

Inhibitor Therapeutics (Inhibitor Therapeutics) Total Stockholders Equity : $4.64 Mil (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Inhibitor Therapeutics Total Stockholders Equity?

Inhibitor Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $4.64 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Inhibitor Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Inhibitor Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.00.


Inhibitor Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Inhibitor Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibitor Therapeutics Total Stockholders Equity Chart

Inhibitor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -3.36 -3.62 8.30 5.28

Inhibitor Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.76 7.11 6.45 5.28 4.64

Inhibitor Therapeutics  (OTCPK:INTI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Inhibitor Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Inhibitor Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inhibitor Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Inhibitor Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Inhibitor Therapeutics (Inhibitor Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
900 West Platt Street, Suite 200, Tampa, FL, USA, 33606-2173
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
Executives
Black Robe Capital Llc 10 percent owner 900 WEST PLATT STREET SUITE 200, TAMPA FL 33606
Ronald E Osman Irrevocable Trust Iii 10 percent owner 1602 WEST KIMMEL, P.O. BOX 939, MARION IL 62959
Ronald E Osman director, 10 percent owner 1602 KIMMEL STREET, MARION IL 62959
Donovan James Joseph Iii 10 percent owner C/O TPB 2012 LLC 12412 POWERSCOURT DR, SUITE 35, SAINT LOUIS MO 63131
Tpb 2012 Llc 10 percent owner 12412 POWERSCOURT DRIVE SUITE 35, SAINT LOUIS MO 63131
Michelle Yanez director 449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Niraj Vasisht director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE., SUITE 225, RALEIGH NC 27612
James A Mcnulty 10 percent owner, officer: See Remarks C/O CV SCIENCES, INC., 2688 S. RAINBOW BLVD., SUITE B, LAS VEGAS NV 89146
Mayne Pharma International Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Ventures Pty Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Mayne Pharma Group Ltd 10 percent owner 1538 MAIN NORTH ROAD, SALISBURY SOUTH, SA C3 5106
Garrison J. Hasara officer: CFO and Treasurer 324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Debra Peattie director 4830 W. KENNEDY BLVD., SUITE 600, TAMPA FL 33609
Robert Daniel Martin director C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
E. Brendan Magrab director, officer: Chairman of the Board C/O HEDGEPATH PHARMACEUTICALS, INC., 324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606